Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044070
Status:
COMPLETED
Last Update Posted:
2006-04-03
First Post:
2002-08-16
Brief Title:
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion Perfusion and FLAIR Magnetic Resonance Imaging in Patients With Acute Ischemic Stroke
Status:
COMPLETED
Status Verified Date:
2006-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will investigate the effects of a potential neuroprotectant compound YM872 in the treatment of acute ischemic stroke The study will determine if a 24-hour infusion of YM872 given within 6 hours of stroke onset reduces the ischemic lesion volume as measured by MRI at 28 days after the infusion is given The clinical effects of YM872 will also be determined by neurological function and disability scores at follow up visits through Day 90 of the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None